T cell receptor T cell therapy

TCR-T therapies use heterodimers made of alpha and beta peptide chains to recognize MHC-presented polypeptide fragment molecules.

[1] In 2024, the US Food and Drug Administration approved afamitresgene autoleucel (Tecelra) as the first TCR-T therapy for the treatment of synovial sarcoma.

Then a TCR phage display library is used to pick TCRs with high affinity and specificity.

[1] Challenges include target selection, TCR identification, affinity screening, safety, time, and cost.

Hybridization (mismatch) between exogenous and endogenous chains may induce harmful recognition of autoantigens, triggering graft-vs.-host disease.